StockNews.AI
ATNM
StockNews.AI
126 days

Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm

1. Kuehn Law investigates potential breaches by ATNM executives. 2. Misrepresentation in Sierra Trial data could impact FDA approval. 3. Insiders allegedly misled shareholders about Iomab-B BLA prospects. 4. Shareholders may have limited time to enforce their rights.

5m saved
Insight
Article

FAQ

Why Very Bearish?

Historical examples show investigations like this often lead to stock price declines.

How important is it?

Legal issues and FDA concerns could critically affect investor confidence and stock performance.

Why Short Term?

Immediate legal scrutiny and potential implications can influence ATNM's price quickly.

Related Companies

IBIOSPPICLVS
, /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Actinium Pharmaceuticals caused the company to misrepresent or fail to disclose that (1) the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate Sierra's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you currently own ATNM and purchased prior to October 31, 2022 please contact Justin Kuehn, Esq. here, by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  Why Your Participation Matters: As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts:Kuehn Law, PLLCJustin Kuehn, Esq.53 Hill Street, Suite 605Southampton, NY 11968[email protected](833) 672-0814 SOURCE Kuehn Law, PLLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News